Skip to main content

Class Action Alleges Valsartan As An Unapproved Drug

Class Action Alleges Valsartan As An Unapproved Drug

Class Action Alleges Valsartan As An Unapproved Drug

Introduction

The valsartan class action lawsuit has alleged that the recalled generic versions of the blood pressure medication distributed in recent years should be considered as an unapproved drug due to the presence of carcinogenic impurities.

According to a complaint filed last week in the U.S. District Court for the District of New Jersey, the plaintiff has alleged that the valsartan manufacturers illegally sold contaminated drugs and falsely advertised them as generic valsartan equivalents, cheating hundreds of thousands of consumers and putting their health at risk. The allegations were on behalf of all Florida residents who purchased recalled generic valsartan products manufactured and distributed by Zhejiang Huahai Pharmaceutical Co., Ltd., Solco Healthcare U.S., and Prinston Pharmaceutical, Inc., who are all defendants in the claim.

There are currently 10 class action lawsuits and one individual action pending in District Courts across the U.S. against Valsartan. Valsartan claims are consolidated under MDL No. 2875 (In re Valsartan Products Liability Litigation) in the United States District Court, District of New Jersey, presided by Judge Robert B. Kugler, U.S.D.J and Hon. Joel Schneider, U.S.M.J.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Talcum Powder Cancer Settlement Talks Begin Sept. 4

Categories: Talcum

Representatives of Johnson & Johnson (J&J) and attorneys for tens of thousands of plaintiffs involved in talcum powder lawsuits are scheduled to meet in September 2025 in an…

Tepezza Hearing Loss Trials Delayed Until Aug 2026

Categories: Tepezza

A series of Tepezza hearing loss lawsuits, which were expected to go before juries next year, will now be delayed. The U.S. District Judge overseeing the multidistrict…

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

✍️ 100% FREE — 60 mins Legal Transcription and 2 Demand Letters!                 
🔒 No AI. No Risk. No Contract. 100% HIPAA-Compliant, Done by Attorneys & Doctors.

Only 06 Slots left for Law Firms—Offer Ends Sep 30!